Global HIV diagnostics market is expected to reach USD 4.48 billion by 2022, growing at an estimated CAGR of 9.5 percent from 2016 to 2022, estimates Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need for development of more sensitive HIV diagnostic point-of-care tests, which can be easily implemented at the location of patient care in resource-limited settings. Technological development of tests which is expected to introduce a number of novel, rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

Antibody HIV diagnostic tests accounted for the largest share of the market in 2014. This large share can be accounted for by the high market usage and penetration rates of these tests, which include ELISA, home access dried blood spot, and western blot testing IFA and RIPA. These tests are highly sensitive and accurate, and thus are most commonly used for screening and confirmation of HIV-1 and HIV-2.

Viral load testing and CD4 testing also accounted for a considerable share of the market in 2014. Further development of these tests will make them more sensitive, rapid in nature, and portable to the point-of-care to enhance their market usability and accessibility in resource-limited HIV-affected regions.

It is expected that during 2016 to 2022, a number of novel point-of-care HIV diagnostic products will be commercialized, which are currently under clinical development and in product pipelines of key market players. This increase in the range of products is expected to fuel the growth of this market over the next 6 years.


 

randox

Digital version